$HIMS

HIMSHims & Hers Health, Inc. Class A Common Stock

YouTube 频道最近怎么谈 Hims & Hers Health(HIMS)?

过去 7 天(截至 11-18),4 个 YouTube 频道谈到 Hims & Hers Health(HIMS),共 4 条。最近一条:Schwab Network,2026-11-18。

本窗口内的全部观点与内容

截至 11-18
11-18
Schwab Network发布 2026-11-18
《Wednesday's Final Takeaways: Gold at 52-Week Lows, Housing Market Mixed》
$HIMS中性
AI 摘要 · HIMS 推出 Peptides Plus,包含五种联合疗法,有望在肽类需求上升之际吸引传统远程医疗之外的新客户并带来经常性收入;但首批疗法均未获 FDA 批准,HIMS 表示安全性、有效性和剂量仍不确定,监管与科学风险可能实质性威胁其增长计划。

Hims&Hers 可能错过了“多肽热潮之夏”,但随着它推出新的“Peptides Plus”平台,提供五种组合疗法,针对从精力与恢复到细胞健康的各种需求,一个“多肽热潮之冬”可能即将到来。

Hims&Hers may have missed out on the " hot peptide summer," but there may be a " hot peptide winter" coming, as it launches its new "Peptides Plus" platform offering five combination therapies targeting everything from energy and recovery to cellular health.

这一举措出台之际,多肽的需求正在上升,但这里存在一个重大障碍。最初的治疗方案均未获得美国食品药品监督管理局(FDA)的批准,公司自己也承认,关于其安全性、有效性和合适剂量,仍有很多需要了解。

This move comes at a time when demand for peptides is increasing, but there is a major obstacle here . None of the initial treatments are approved by the Food and Drug Administration (FDA), and the company itself acknowledges that there is still much to learn about their safety, effectiveness, and appropriate dosages .

11-17
Verified Investing发布 2026-11-17
《MAJOR EARNINGS FOR NVIDIA (Silver Bottom?)》
$HIMS看涨
AI 摘要 · HIMS 自 5 月前不久起处于下跌趋势,尽管业绩尚可,股价仍下跌且仍在下跌;说话者只会在其跌至约 18 美元时买入,视其为潜在支撑区域。

所以,在市场整体小幅反弹的情况下,我在找一些可能下跌且位置稍低的标的,那就是HIMS。从今年5月之前一路延伸过来,有一条漂亮的下降趋势线,穿过这里,穿过这里,然后最终在下方寻找潜在支撑区域。

So with the markets generally kind of bouncing a little bit, I'm looking at something that might fall and is a little lower and that's HIMS HIMS. You have a nice downs sloping trend line from all the way back here just before May of this year coming through here coming through here and then finally looking for an area for potential support down here.

11-13
《NVDA Fallout: Where Is the Smart Money Going? | Market Pulse Nov. 13, 2026》
$HIMS看跌
AI 摘要 · HIMS 曾长期上涨,但在模糊记得的账户相关问题之后,连续数周下跌,并在衰竭缺口处跳空低开;说话者得出结论,它尚未恢复。

我们来看看“Hems”这家公司。它叫“Hems & Hers Health”。现在看这张图,不是吗?很明显,这张图已经向上趋势了很长时间。他们遇到了账户之类的一些问题。我记不清了。

但看看那连续数周的下跌,直到该股最终跳空低开,那是一个衰竭缺口。它真的没能恢复,对吧?

Let's take a look at the "Hems" company. It's called " [17:18] Hems & Hers Health". Now look at this [17:21] graph, don't you? It is clear that [17:24] this chart has been trending upwards for a long time [17:27] .

They encountered some problems with the accounts or something like that [17:29] . I can't remember. But [17:32] look at all those consecutive weeks of [17:35] decline, until the stock eventually gapped down [17:37] , and that was an exhaustion gap. He [17:39] really couldn't recover, did he?

Parkev Tatevosian, CFA发布 2026-11-13
《Why Is Hims Stock Crashing, and is it a Buying Opportunity?》
$HIMS看涨
AI 摘要 · HIMS 仍是买入机会,但他的信心已从中等降至低,原因是费用增速快于收入:G&A 几乎翻倍至 1.515 亿美元,营业利润从 1180 万美元降至 -6600 万美元,经营现金流从 2.39 亿美元降至 1.19 亿美元,因此约 18% 的下跌是合理的。尽管收入增长 49%、订阅用户增长 13%、每订阅用户收入提高 30%,但在 19 美元价位,该股相对他略高于 22 美元的合理价值以及 25.4 倍的远期市盈率仍被低估。

Hems & Hers 公布了季度财务业绩,令股市投资者感到失望。营收增长了49%,订阅用户增长了13%,但费用也增加了,现金流则大幅下降。

Hems & Hers announced quarterly financial results that disappointed investors in the stock market. Revenues increased by 49% and subscribers by 13%, but expenses also increased and cash flow decreased significantly.

投资者惩罚了这只股票,在公司公布这些数据后的第二天,股价下跌了约19%。所以我想分享一下我对 Heams & Hers 股票的评级,我认为这次股价下跌后是否构成了买入机会,以及我对该公司公允价值的估计。

Investors punished the stock, which fell by about 19 % the day after the company announced these figures. So I wanted to share my rating of Heams & Hers stock, whether I think this represents a buying opportunity after the price drop , and what my estimate of the company's fair value is.

他说在等
电话会议记录中对一般及行政费用(G&A)为何近乎翻倍的解释
成本上升与收购相关,而非结构性问题
下一次财报电话会议记录
支持买入逻辑
已显示 4 / 本页 4 条
看这只股票的全部记录